Moderna stock soared on a strong fourth-quarter report that included unexpected earnings. Is MRNA stock a buy or a sell right now?
The CDC’s vaccine advisory committee could offer clues about an eventual call on how often the vaccines are needed.
Moderna shares were trading lower after a Wall Street firm turned bearish on the vaccine maker days after it issued strong quarterly results. HSBC Global Research analysts led by Yifeng Liu downgraded Moderna to Reduce from Hold but raised their price target to $86 from $75 in a Monday report. Moderna stock was down 3.8% to $92.78 in early afternoon trading, while Pfizer another maker of vaccines for Covid-19, was off 2%.